Literature DB >> 25585596

The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.

Klaudia Farkas1, Zoltán Saródi1, Anita Bálint1, Imre Földesi1, László Tiszlavicz2, Mónika Szűcs3, Tibor Nyári3, János Tajti4, Ferenc Nagy1, Zoltán Szepes1, Renáta Bor1, Anita Annaházi1, Richárd Róka1, Tamás Molnár5.   

Abstract

BACKGROUND: Only limited data are available regarding the diagnostic accuracy of fecal matrix metalloprotease-9 [MMP-9] for inflammatory bowel disease [IBD]. The aims of our study were to assess the diagnostic accuracy of fecal MMP-9 in patients with active Crohn's disease [CD], ulcerative colitis [UC], and pouchitis, and to compare the diagnostic accuracy of fecal MMP-9 and fecal calprotectin [CP] in IBD.
METHODS: Stool and blood samples were collected in 50 CD, 54 UC, and 34 ileal pouch-anal anastomosis patients before control endoscopies were performed. Biopsies were taken for histologic purposes. The activities of CD, UC, and pouchitis were defined with the use of clinical, endoscopic, and histologic activity scores. Fecal CP and MMP-9 levels were quantified by enzyme-linked immunosorbent assay.
RESULTS: Active CD, UC, and pouchitis were detected in 38%, 54%, and 29% of the patients, respectively. A significant correlation was revealed between fecal CP and the clinical activities of CD and UC, and between fecal CP and the endoscopic activity of UC and pouchitis. Fecal MMP-9 did not correlate with any of the activity indices of CD; however, strong associations were shown between fecal MMP-9 and clinical, endoscopic, and histologic activities of both UC and pouchitis.
CONCLUSIONS: This is the first study assessing the diagnostic accuracy of MMP-9 in different types of IBD. Our results showed that fecal MMP-9 has high sensitivity in the detection of endoscopically active UC and pouchitis. These non-invasive methods help assess intestinal inflammation.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; calprotectin; matrix metalloprotease-9; pouchitis; ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 25585596     DOI: 10.1093/ecco-jcc/jjv005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  17 in total

1.  Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?

Authors:  Aleksandra Czajkowska; Katarzyna Guzinska-Ustymowicz; Anna Pryczynicz; Dariusz Lebensztejn; Urszula Daniluk
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

Review 2.  [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].

Authors:  S Schreiber
Journal:  Z Rheumatol       Date:  2015-10       Impact factor: 1.372

Review 3.  Matrix metalloproteinases in inflammatory bowel disease: an update.

Authors:  Shane O'Sullivan; John F Gilmer; Carlos Medina
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

Review 4.  The Dual Role of Neutrophils in Inflammatory Bowel Diseases.

Authors:  Odile Wéra; Patrizio Lancellotti; Cécile Oury
Journal:  J Clin Med       Date:  2016-12-17       Impact factor: 4.241

Review 5.  Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface.

Authors:  Vassilis Valatas; Eirini Filidou; Ioannis Drygiannakis; George Kolios
Journal:  Ann Gastroenterol       Date:  2017-04-12

Review 6.  Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.

Authors:  Gilles Duvoisin; Robert N Lopez; Andrew S Day; Daniel A Lemberg; Richard B Gearry; Steven T Leach
Journal:  Mediators Inflamm       Date:  2017-04-16       Impact factor: 4.711

7.  Identification of matrix metalloproteinase-2 and -9 activities within the intestinal mucosa of dogs with chronic enteropathies.

Authors:  Mohsen Hanifeh; Minna Marjaana Rajamäki; Pernilla Syrjä; Laura Mäkitalo; Susanne Kilpinen; Thomas Spillmann
Journal:  Acta Vet Scand       Date:  2018-03-12       Impact factor: 1.695

8.  Disease Activity Indices for Pouchitis: A Systematic Review.

Authors:  Rocio Sedano; Tran M Nguyen; Ahmed Almradi; Florian Rieder; Claire E Parker; Lisa M Shackelton; Geert D'Haens; William J Sandborn; Brian G Feagan; Christopher Ma; Vipul Jairath
Journal:  Inflamm Bowel Dis       Date:  2022-03-30       Impact factor: 7.290

Review 9.  Angiogenesis in Inflammatory Bowel Disease.

Authors:  Canan Alkim; Huseyin Alkim; Ali Riza Koksal; Salih Boga; Ilker Sen
Journal:  Int J Inflam       Date:  2015-12-29

10.  Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.

Authors:  W J Sandborn; B R Bhandari; R Fogel; J Onken; E Yen; X Zhao; Z Jiang; D Ge; Y Xin; Z Ye; D French; J A Silverman; B Kanwar; G M Subramanian; J G McHutchison; S D Lee; L M Shackelton; R K Pai; B G Levesque; B G Feagan
Journal:  Aliment Pharmacol Ther       Date:  2016-05-24       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.